Rare Diseases, Aifa Approves the Refundability of the First Therapy for Acid Lipase Deficiency
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.8 Articles
8 Articles
The Italian Medicines Agency (Aifa) has approved the refundability in Italy of sebelipase alfa for the treatment of lysosomal acid lipase deficiency (LAL-D). Long-term enzyme replacement therapy is indicated for patients of all ages and is the first treatment available in the country for this ultra-rare and progressive genetic metabolic disease caused by a defect of the enzyme that allows to metabolize cholesterol and triglycerides. This failure…
Italian Drug Agency (Aifa) approved the refundability in Italy of sebelipase alfa for the treatment of lysosomal acid lipase deficiency
(The following text is taken in full from the press note sent to the Agency Opinion) //// The Board of Directors of AIFA has given the green light to the refundability of various therapeutic options, including an orphan drug for rare diseases, six new therapeutic indications with particular regard to the paediatric population and equivalent drugs. It will be refunded by the National Health Service [...]
Rec News | Lontani dal mainstream
(Adnkronos) - The Italian Medicines Agency (Aifa) has approved the refundability of sebelipase alfa, a long-term enzyme replacement therapy indicated for the treatment of patients of all ages with lysosomal acid lipase deficiency (Lal-D). Sebelipase alfa - informs Alexion, AstraZeneca Rare Disease in a note is the first treatment [...] The article Deficit of lysosomal acid lipase, Aifa approves reimbursement for sebelipase alfa comes from Rec Ne…
New therapeutic options for oncology, HIV-1 infection, mental health in adolescents and rare diseases are clear. The Board of Directors has approved patented expired medicines that generate a reduction in pharmaceutical spending estimated at 38.2 million euros. THE DOCUMENT The post The AIFA Board of Directors approves the refundability for a new orphan drug, 6 indication extensions also in children and 3 equivalent appeared first on Quotidiano …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
